Dyadic International (NASDAQ:DYAI) Stock Crosses Below Fifty Day Moving Average – Time to Sell?

Shares of Dyadic International Inc. (NASDAQ:DYAI) passed below its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $0.89 and traded as low as $0.79. Dyadic International shares last traded at $0.8115, with a volume of 131,094 shares.

Analysts Set New Price Targets

DYAI has been the subject of several recent research reports. HC Wainwright assumed coverage on Dyadic International in a report on Thursday, October 23rd. They issued a “buy” rating and a $3.00 price target for the company. Weiss Ratings restated a “sell (e+)” rating on shares of Dyadic International in a research note on Monday, December 29th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $3.00.

Dyadic International Trading Up 0.8%

The stock has a market cap of $29.37 million, a P/E ratio of -3.38 and a beta of 1.27. The company has a debt-to-equity ratio of 1.92, a current ratio of 2.85 and a quick ratio of 2.85. The business’s 50 day simple moving average is $0.89 and its 200 day simple moving average is $0.96.

Institutional Trading of Dyadic International

A number of large investors have recently bought and sold shares of DYAI. Geode Capital Management LLC raised its stake in Dyadic International by 13.7% during the fourth quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock worth $284,000 after acquiring an additional 36,266 shares in the last quarter. Marathon Capital Management grew its holdings in shares of Dyadic International by 142.9% in the 4th quarter. Marathon Capital Management now owns 85,000 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 50,000 shares during the last quarter. Apis Capital Advisors LLC acquired a new stake in shares of Dyadic International during the 3rd quarter worth about $1,817,000. Landscape Capital Management L.L.C. acquired a new stake in shares of Dyadic International during the 3rd quarter worth about $190,000. Finally, Truist Financial Corp lifted its holdings in Dyadic International by 30.5% during the 3rd quarter. Truist Financial Corp now owns 326,200 shares of the biotechnology company’s stock valued at $385,000 after purchasing an additional 76,200 shares during the last quarter. 27.95% of the stock is currently owned by institutional investors.

About Dyadic International

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.